ESC 365 - One year after: what are the implications of the new The ESC/EAS LDL-c Guidelines for PCSK9i?

Open Access

One year after: what are the implications of the new The ESC/EAS LDL-c Guidelines for PCSK9i?

Session: PCSK9i & LDL-c: Guidelines, Practice & Innovation: Review of facts and opportunities

Topic: Lipid-Lowering Agents

Speaker: Professor F. Mach (Geneva, CH)

Organised by PACE-CME, supported by Amgen and Sanofi in the form of an educational grant

Event: ESC Congress 2020

Congress Presentation

Add to my library

About the speaker

Professor Francois Mach

University hospitals of Geneva, Geneva (Switzerland)

24 presentations

14 followers

4 more presentations in this session

Introduction.

Speaker: Professor J. Kastelein (Amsterdam, NL)

Five years of PCSK9i: Lessons from practice, which patients do benefit most?

Speaker: Professor E. Stroes (Amsterdam, NL)

Time to reduce the implementation gaps-the role of PCSK9i in routine practice

Speaker: Professor K. Ray (London, GB)

Discussion.

Speaker: Professor J. Kastelein (Amsterdam, NL)

Access the full session

PCSK9i & LDL-c: Guidelines, Practice & Innovation: Review of facts and opportunities

Speakers: Professor F. Mach, Professor J. Kastelein, Professor E. Stroes, Professor K. Ray, Professor J. Kastelein

About the event

ESC Congress 2020

29 August - 1 September 2020

Sessions Presentations

Congress

ESC 365 is supported by

bristol-myers-squibb

Explore sponsored resources

novartis

Explore sponsored resources